CELC

Celcuity Inc. Common Stock (CELC)

Stock · NASDAQ · Health Care

$56.58as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 10, 2026

Celcuity Shares Fall 17% After REVTORPYK Launch and NDA Filing. Celcuity’s stock fell 17.3% after the company announced the launch of its REVTORPYK product in the U.S. and filed a new drug application. The company also said it will present at the European Society for Medical Oncology congress, adding to the mix of upcoming events. With the price near its 14‑day support level of $87.46 and an RSI of 30.1, the move reflects a short‑term reaction to the news rather than a long‑term trend.

Price chart

Open in TradingView

Active signals

200 SMA Touch0.0%
Resistance level
$86.75
Industry
Medical Specialities

CELC Signal Track Record

How signals performed across all stocks →

What CELC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike43+1.2%53%
Bollinger Band Breakout28+1.3%54%
Bollinger Band Breakdown17+5.7%65%
200-Day Moving Average TouchActive now18-4.7%39%
Any 20-session window (baseline)+2.3%57%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About CELC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients wi…

Sector
Health Care
Industry
Medical Specialities
Employees
155

Fundamentals

1-day range
$53.54$60.23
Market cap
$4.55B
P/E (trailing)
—
P/E (forward)
-707.25
EPS (trailing)
$-4.30
Dividend yield
—
Beta
0.10
Avg. volume
1.11M
52-week range
$46.51$151.02
Next earnings: November 11, 2026 · EPS estimate $-1.51After Closeconfirmed

Forecasts

11 analyst ratings

Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$177
+212.8%
Median
$157
+177.5%
Low
$130
+129.8%

Celcuity Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • CELC
    Celcuity Inc. Common Stock
    $56.58
    ▼ 6.17%
    Market cap $4.55BP/E —
    $46.51$151.02
  • BLLN
    BillionToOne Inc. Class A Common Stock
    $98.12
    ▼ 4.49%
    Market cap $4.22BP/E 128.54
    $61.96$150.44
  • CON
    Concentra Group Holdings Parent Inc. Common Stock
    $38.54
    ▼ 1.56%
    Market cap $3.91BP/E 24.09
    $18.55$38.07
  • RDNT
    RadNet Inc. Common Stock
    $68.8
    ▼ 2.29%
    Market cap $5.36BP/E —
    $50.82$85.84
  • VCYT
    Veracyte Inc. Common Stock
    $43.12
    ▼ 2.86%
    Market cap $3.71BP/E 31.17
    $29.46$60.91
  • CAI
    Caris Life Sciences Inc. Common Stock
    $30.56
    ▼ 3.78%
    Market cap $5.65BP/E 76.07
    $14.19$33.66
  • ACHC
    Acadia Healthcare Company Inc. Common Stock
    $29.98
    ▼ 3.41%
    Market cap $2.86BP/E —
    $11.43$35.83

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
263.6K
Disposed
3.13M

Institutional Ownership

March 31, 2026

Total shares held
50.76M
Total value held
$5.55B
Institutional holders
271
Top holders this quarter
  • Unknown7.92M
  • Unknown3.58M
  • Unknown3.13M
  • Unknown3.04M
  • Unknown2.71M
  • Unknown2.29M
  • Unknown1.78M
  • Unknown1.71M
  • Unknown1.52M
  • Unknown1.35M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.